Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 10;3(1):142-150.
doi: 10.1016/j.xkme.2020.10.001. eCollection 2021 Jan-Feb.

Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation

Jeffrey C Weinreb  1   2 , Roger A Rodby  3   4 , Jerry Yee  3   5 , Carolyn L Wang  1   6 , Derek Fine  3   7 , Robert J McDonald  1   8 , Mark A Perazella  3   9 , Jonathan R Dillman  1   10 , Matthew S Davenport  1   11   12   13
Affiliations
Review

Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation

Jeffrey C Weinreb et al. Kidney Med. .

Abstract

Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m2; upper bounds of the 95% confidence intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and no dialysis). No unconfounded cases of NSF have been reported for the only available group III GBCM (gadoxetate disodium). Depending on the clinical indication, the potential harms of delaying or withholding group II or group III GBCM for an MRI in a patient with acute kidney injury or eGFR less than 30 mL/min per 1.73 m2 should be balanced against and may outweigh the risk of NSF. Dialysis initiation or alteration is likely unnecessary based on group II or group III GBCM administration.

PubMed Disclaimer

References

    1. Balzer T. U.S. Food and Drug Administration; Silver Spring, Md: 2017. Presence of gadolinium (Gd) in the brain and body. Presentation to the Medical Imaging Drugs Advisory Committee, FDA.
    1. McDonald R.J., Levine D., Weinreb J. Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology. 2018;289(2):517–534. - PMC - PubMed
    1. Maripuri A., Jahansen K.L. Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease-Is Zero Good Enough? JAMA Intern Med. 2020;180(2):230–232. - PubMed
    1. Davenport M.S., Perazella M.A., Yee J. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med. 2020;2(1):85–93. - PMC - PubMed
    1. Rogosnitzky M., Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016;29(3):365–376. - PMC - PubMed